NovoLISA (de Novo protein-Linked Instantaneous Solution-based Assay) Platform for Life Sciences Research and Diagnostics - NovoLISA is a rapid, single-step biosensor assay for research use only applications SEATTLE , Sept. 30, 2024 /PRNewswire/ -- Monod Bio, a life sciences company using AI to generate new proteins for the research use only (RUO) and in vitro diagnostics (IVD) markets, announced today the launch of the NovoLISA, a rapid biosensor assay platform that delivers results in just 15 minutes—drastically reducing the time to result when compared with alternative methods, such as the ELISA assay platform often used in RUO settings. The name of the platform, NovoLISA, stands for " de Novo protein-Linked Instantaneous Solution-based Assay".
The Company is launching the NovoLISA platform with its first offering of a C-Reactive Protein (CRP) assay. The NovoLISA combines two proprietary technologies: the LuxSitTM Pro luciferase reporter and de novo binding protein reagents. This combination forms a uniquely fast assay with an easy-to-use format.
Key features of the new NovoLISA platform include 1) results in 15 minutes or less, 2) simple, one step, no wash protocol, 3) no need for sample preparation, and 4) a readout in the common laboratory luminescence plate reader. Alfredo-Quijano Rubio , Ph.D.
, CSO and co-founder of Monod Bio, said, "NovoLISA brings a new generation of assays to the laboratory. The AI platform used to develop the de novo binders creates sensors that .